ADMA Biologics Inc vs Advanced Drainage Systems Inc — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while Advanced Drainage Systems Inc trades at $143.7 (market cap $10.68B). The key difference: Advanced Drainage Systems Inc is far larger — about 4.9× ADMA Biologics Inc's market cap, and Advanced Drainage Systems Inc pays a 0.56% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | WMS | |
|---|---|---|
Market Cap | $2.18B | $10.68B |
Sector | Health | Industrials |
52-Week High | $20.38 | $175.38 |
52-Week Low | $7.60 | $129.50 |
Enterprise Value | $2.25B | $12.29B |
Dividend Yield | — | 0.56% |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
Advanced Drainage Systems (WMS) trades at $143.95, down 3.03% on the day, with a neutral technical signal. The company reported strong Q2 2026 earnings of $2.49 per share, beating estimates, and maintains solid profitability with a 14% net income margin and 24.9% ROE. Recent news highlights Q1 fiscal 2027 sales growth of 21% and consistent dividend payments, though cash flow turned negative in 2025 due to increased investing activity.
The outlook is mixed; analyst consensus is a Buy with a $185.86 price target, but near-term risks include volatile cash flows and high valuation multiples. Upside potential hinges on execution of growth initiatives and infrastructure demand, while margin pressure and economic sensitivity pose challenges.
Trailing returns across standard periods
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe
Read more on WMS →